Upstream Bio (NASDAQ:UPB) Trading 7.8% Higher – Time to Buy?

Upstream Bio, Inc. (NASDAQ:UPB)’s share price was up 7.8% on Wednesday . The stock traded as high as $27.90 and last traded at $27.88. Approximately 171,905 shares traded hands during trading, a decline of 63% from the average daily volume of 469,139 shares. The stock had previously closed at $25.87.

Analysts Set New Price Targets

Several analysts have recently issued reports on UPB shares. Mizuho upgraded Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Lifesci Capital began coverage on shares of Upstream Bio in a research note on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price for the company. Truist Financial initiated coverage on shares of Upstream Bio in a research note on Tuesday, October 14th. They set a “buy” rating and a $47.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, October 8th. Finally, Evercore ISI initiated coverage on shares of Upstream Bio in a research note on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Stock Performance

The firm has a fifty day simple moving average of $26.87 and a 200 day simple moving average of $20.05. The company has a market cap of $1.47 billion, a PE ratio of -14.51 and a beta of 1.90.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.15. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. The business had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.65 million. As a group, equities analysts predict that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.

Institutional Trading of Upstream Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC grew its holdings in shares of Upstream Bio by 6.3% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock worth $26,786,000 after purchasing an additional 144,216 shares during the period. Geode Capital Management LLC lifted its position in Upstream Bio by 57.5% during the second quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock valued at $7,101,000 after buying an additional 235,958 shares in the last quarter. Norges Bank acquired a new position in Upstream Bio during the second quarter valued at approximately $10,650,000. Virtus Investment Advisers LLC purchased a new stake in Upstream Bio during the second quarter worth approximately $89,000. Finally, Police & Firemen s Retirement System of New Jersey increased its position in shares of Upstream Bio by 133.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 7,833 shares of the company’s stock worth $86,000 after acquiring an additional 4,483 shares in the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.